-
公开(公告)号：US4906474A
公开(公告)日：1990-03-06
申请号：US613001
申请日：1984-05-21
申请人： Robert S. Langer , Howard Rosen , Robert J. Linhardt , Kam Leong
发明人： Robert S. Langer , Howard Rosen , Robert J. Linhardt , Kam Leong
摘要： A composition of matter suitable for implantation in the body to effect zero order drug release comprising a drug and a polymer of the formula: ##STR1## wherein R and R' can be the same or different and are hydrophobic organic linkages and n and m are integers of 1 or greater.
摘要翻译： 适于植入体内以实现零级药物释放的物质组合物，其包含药物和下式的聚合物：其中R和R'可以相同或不同，并且是疏水性有机键，并且n和m是 1或更大的整数。
-
2.再颁专利公开(公告)号：USRE41328E1
公开(公告)日：2010-05-11
申请号：US12199215
申请日：2008-08-27
申请人： Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer , Daniel L. Lohse , Robert J. Linhardt
发明人： Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer , Daniel L. Lohse , Robert J. Linhardt
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A purified heparinase I, II and III free of lyase activity and each having a molecular weight of 42,800 84,100, 70,800, respectively, are produced by culturing Flavobacterium heparinum. The kinetic properties of the heparinases have been determined as well as the conditions to optimize their activity and stability.
摘要翻译： 不含裂解酶活性的纯化肝素酶I，II和III分别通过培养肝炎黄杆菌而产生，分子量分别为42,400,84,100,70,800。 已经确定了肝素酶的动力学性质以及优化其活性和稳定性的条件。
-
3.再颁专利Purification, composition and specificity of Heparinase I, II, and III from Flavobacterium heparinum 有权来自肝炎黄杆菌的肝素酶I，II和III的纯化，组成和特异性公开(公告)号：USRE41461E1
公开(公告)日：2010-07-27
申请号：US12199157
申请日：2008-08-27
申请人： Daniel L. Lohse , Robert J. Linhardt , Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer
发明人： Daniel L. Lohse , Robert J. Linhardt , Ramnath Sasisekharan , Charles L. Cooney , Robert S. Langer
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Mono-clonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.
摘要翻译： 本文公开了将来自肝素肝素的所有三种肝素裂解酶同时纯化到表观均一性的单一可再现方案。 已经确定了肝素裂解酶的动力学性质以及优化其活性和稳定性的条件。 还描述了对三种肝素酶的单克隆抗体，并且其可用于肝素酶的检测，分离和表征。
-
4.发明授权
公开(公告)号：US5569600A
公开(公告)日：1996-10-29
申请号：US378789
申请日：1995-01-26
申请人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
发明人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
IPC分类号： G01N33/573 , C07K16/40 , C12N9/88 , C12P19/26 , C12P21/08 , C12R1/20 , C12R1/91 , C12N9/00 , C12N1/20 , C12N9/52
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A single, reproducible scheme to simultaneously purify all three of the heparin lyases from F. heparinum to apparent homogeneity is disclosed herein. The kinetic properties of the heparin lyases have been determined as well as the conditions to optimize their activity and stability. Monoclonal antibodies to the three heparinases are also described and are useful for detection, isolation and characterization of the heparinases.
摘要翻译： 本文公开了将来自肝素肝素的所有三种肝素裂解酶同时纯化到表观均一性的单一可再现方案。 已经确定了肝素裂解酶的动力学性质以及优化其活性和稳定性的条件。 还描述了三种肝素酶的单克隆抗体，并且其可用于肝素酶的检测，分离和表征。
-
5.发明授权
公开(公告)号：US5389539A
公开(公告)日：1995-02-14
申请号：US983367
申请日：1992-11-30
申请人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
发明人： Ramnath Sasisekharan , Daniel L. Lohse , Charles L. Cooney , Robert J. Linhardt , Robert S. Langer
IPC分类号： G01N33/573 , C07K16/40 , C12N9/88 , C12P19/26 , C12P21/08 , C12R1/20 , C12R1/91 , C12N9/00 , C12N1/20 , C12N9/52
CPC分类号： C12N9/88 , Y10S435/822 , Y10S435/85
摘要： A purified heparinase I, II and III free of lyase activity and each having a molecular weight of 42,800 84,100, 70,800, respectively, are produced by culturing Flavobacterium heparinum. The kinetic properties of the heparinases have been determined as well as the conditions to optimize their activity and stability.
摘要翻译： 不含裂解酶活性的纯化的肝素酶I，II和III分别通过培养肝素肝素而产生，分子量分别为42,600 84,100,70,800。 已经确定了肝素酶的动力学性质以及优化其活性和稳定性的条件。
-
公开(公告)号：US4396762A
公开(公告)日：1983-08-02
申请号：US295914
申请日：1981-08-24
CPC分类号： A61K31/715 , C08B37/0078 , Y10S435/85
摘要： There is disclosed a heparin product obtained by degradation of heparin with heparinase from Flavobacterium heparinum (ATCC 13125) or mutants thereof having activity to reduce the coagulation activity of factor X while not effecting the coagulation activity of thrombin.
摘要翻译： 公开了通过肝素从肝素黄素（ATCC13125）或其突变体用肝素酶降解获得的肝素产物，其具有降低因子X的凝血活性而不影响凝血酶凝血活性的活性。
-
公开(公告)号：US4891225A
公开(公告)日：1990-01-02
申请号：US820290
申请日：1986-01-21
申请人： Robert S. Langer , Howard Rosen
发明人： Robert S. Langer , Howard Rosen
摘要： A novel hydrophobic polymeric matrix is provided which is suitable for use after implantation in vivo in a subject for the controlled release and delivery of biologically active substances such as drugs, antibiotics, steroids and the like. Alternatively, the matrix can be used outside the body for release of fragrances, pesticides and the like. The implantable matrix comprises a polymeric polyanhydride formulation whose internal anhydride linkages are hydrolytic in nature in varying degrees in accordance with the chemical composition of the backbone, pH and temperature of the environment. As the individual anhydride linkages become hydrolyzed, the matrix erodes predominantly by surface erosion into non-toxic biocompatible degradation products with concomitant release of the biologically active substance.
摘要翻译： 提供了一种新颖的疏水性聚合物基质，其适用于受试者体内植入后用于生物活性物质如药物，抗生素，类固醇等的控制释放和递送。 或者，可以在体外使用基质以释放香料，农药等。 可植入基质包含聚合多酸酐制剂，其内酸酐键根据骨架的化学组成，pH和环境温度在不同程度上水解。 当单个酸酐键变得水解时，基质主要通过表面侵蚀侵蚀成无毒的生物相容性降解产物，同时释放生物活性物质。
-
公开(公告)号：US10696944B2
公开(公告)日：2020-06-30
申请号：US14352354
申请日：2012-10-17
申请人： Massachusetts Institute of Technology , Armon R. Sharei , Andrea Adamo , Robert S. Langer , Klavs F. Jensen
摘要： A microfluidic system for causing perturbations in a cell membrane, the system including a microfluidic channel defining a lumen and being configured such that a cell suspended in a buffer can pass therethrough, wherein the microfluidic channel includes a cell-deforming constriction, wherein a diameter of the constriction is a function of the diameter of the cell.
-
公开(公告)号：US09333179B2
公开(公告)日：2016-05-10
申请号：US12573591
申请日：2009-10-05
申请人： Liangfang Zhang , Aleksandar F. Radovic-Moreno , Frank X. Gu , Frank Alexis , Robert S. Langer , Omid C. Farokhzad
发明人： Liangfang Zhang , Aleksandar F. Radovic-Moreno , Frank X. Gu , Frank Alexis , Robert S. Langer , Omid C. Farokhzad
CPC分类号： A61K9/5123 , A61K9/5153 , A61K9/5192 , A61K47/62 , A61K47/6935 , A61K47/6937 , B82Y5/00
摘要： The present invention generally relates to nanoparticles with an amphiphilic component. One aspect of the invention is directed to a method of developing nanoparticles with desired properties. In one set of embodiments, the method includes producing libraries of nanoparticles having highly controlled properties, which can be formed by mixing together two or more macromolecules in different ratios. One or more of the macromolecules may be a polymeric conjugate of a moiety to a biocompatible polymer. In some cases, the nanoparticle may contain a drug. Other aspects of the invention are directed to methods using nanoparticle libraries.
摘要翻译： 本发明通常涉及具有两亲性组分的纳米颗粒。 本发明的一个方面涉及一种开发具有所需性质的纳米颗粒的方法。 在一组实施方案中，该方法包括制备具有高度控制性质的纳米颗粒的文库，其可通过将两种或多种不同比例的大分子混合在一起形成。 一个或多个大分子可以是部分与生物相容性聚合物的聚合物缀合物。 在一些情况下，纳米颗粒可以含有药物。 本发明的其它方面涉及使用纳米颗粒文库的方法。
-
公开(公告)号：US09216188B2
公开(公告)日：2015-12-22
申请号：US12553800
申请日：2009-09-03
IPC分类号： A61K9/00 , A61K31/00 , A61K31/7052 , A61L27/26 , A61L27/38 , A61L27/52 , C08J3/075 , C08J3/24
CPC分类号： A61L27/26 , A61K31/00 , A61K31/7052 , A61L27/38 , A61L27/3834 , A61L27/50 , A61L27/52 , A61L2400/06 , A61L2430/34 , C08J3/075 , C08J3/246 , C08J2305/08 , C08J2371/02 , C08L71/02
摘要： The present invention provides hydrogels and compositions thereof for vocal cord repair or augmentation, as well as other soft tissue repair or augmentation (e.g., bladder neck augmentation, dermal fillers, breast implants, intervertebral disks, muscle-mass). The hydrogels or compositions thereof are injected into the superficial lamina propria or phonatory epithelium to restore the phonatory mucosa of the vocal cords, thereby restoring a patient's voice. In particular, it has been discovered that hydrogels with an elastic shear modulus of approximately 25 Pa are useful in restoring the pliability of the phonatory mucosa. The invention also provides methods of preparing and using the inventive hydrogels.
摘要翻译： 本发明提供水凝胶及其组合物，用于声带修复或增强，以及其它软组织修复或增强（例如，膀胱颈增大，皮肤填充剂，乳房植入物，椎间盘，肌肉质量）。 将水凝胶或其组合物注射到表层固有层或声音上皮中以恢复声带的声音粘膜，从而恢复患者的声音。 特别地，已经发现弹性剪切模量为约25Pa的水凝胶可用于恢复发音粘膜的柔韧性。 本发明还提供了制备和使用本发明水凝胶的方法。
-
-
-
-
-
-
-
-
-
搜索结果
351 条记录 (耗时 0.061 秒)
